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Efficacy of brodalumab in moderate-to-severe plaque psoriasis
after failure of previous biologic therapies: A phase IV, multicenter, open-label study
Kim Papp, MD, Probity Medical Research, Waterloo, ON, Canada; Vimal
H. Prajapati, MD, Division of Dermatology, Department of Medicine, University
of Calgary, Calgary, AB, Canada; Section of Community Pediatrics, Department of
Pediatrics, University of Calgary, Calgary, AB, Canada; Section of Pediatric
Rheumatology, Department of Pediatrics; Catherine Maari, MD, Department of
Dermatology and Skin Science, University of Montreal, Montreal, QC, Canada;
Innovaderm Research Inc, Montreal, QC, Canada
Despite the high efficacy of biologic therapies in the management of moderate-tosevere plaque psoriasis (PsO), some patients will not achieve skin clearance with
their treatment. It is therefore important to understand efficacy of a certain biologic
therapy after switching from a previous biologic. A phase IV, 26-week, multicentre,
open-label study is underway in Canada to evaluate effectiveness of the interleukin
(IL)-17 receptor A antagonist brodalumab (210 mg subcutaneous injection at weeks
0, 1, and 2, then every 2 weeks) in moderate-to-severe plaque PsO patients with
inadequate response to at least one previous biologic. This interim analysis includes
data from the first 228 patients enrolled, including 134 completers who were last
treated with a biologic targeting IL-12/23 (n ¼ 21), IL-23 (n ¼ 25), IL-17 (n ¼ 63), or
tumor necrosis factor-alpha (n ¼ 25). Mean PASI and BSA at baseline were 10.3 and
14.8%, respectively. At week 26, 44.8% of patients achieved the primary endpoint of
PASI 100 (estimated mean time of 94.5 days) and mean BSA was 3.4%, while 67.9% of
patients were rated clear or almost clear on the sPGA. At the time of this analysis, 63
patients previously treated with another IL-17 inhibitor had reached the 26-week
endpoint, with 41.3% achieving PASI 100 with brodalumab (estimated mean time of
102.8 days). Adverse events were reported by 58% of patients (7.5% discontinued),
with the majority being mild or moderate in severity. These results provide evidence
that patients switched to brodalumab after inadequate response to a previous
biologic have the potential to achieve clear skin.
Commercial Disclosure: Clinical trial sponsored by Bausch Health Canada.
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Efficacy of intravenous immunoglobulins (IVIG) in improving
muscle and skin symptoms in dermatomyositis patients. Results
of a large, randomized, placebo-controlled international phase
III trial (ProDERM)
Victoria Werth, University of Pennsylvania and Corporal Michael J. Crescenz
VAMC; Margitta Worm, MD, Clinic for Dermatology, Venerology and Allergology,
Charite Berlin; Rohit Aggarwal, MD, University of Pittsburgh School of Medicine,
Pittsburgh, PA
Dermatomyositis (DM) is a rare chronic systemic autoimmune disease with
characteristic skin rashes and progressive proximal muscle weakness. The
ProDERM study evaluated the efficacy and safety/tolerability of IVIG
(Octapharma) in DM patients in a double-blind, randomized, placebo-controlled,
international, phase III clinical trial consisting of a First Period (16 weeks; doubleblind, placebo-controlled) and subsequent Extension Period (24 weeks; open label
e all IVIG). Patients received a total of 10 infusions (only IVIG or placebo-IVIG).
Primary endpoint was the proportion of responders in Total-Improvement-Score
(TIS) in IVIG vs. placebo arm at week 16. Secondary endpoints included mean
change in CDASI from baseline (Week-0) to end of First Period (Week-16). Ninety-five
adult DM patients (mean age: 53 years; 75% females) were enrolled (47-IVIG/48placebo). Clinical baseline characteristics (e.g. mean CDASI scores) were similar in
both arms. At week 16, number of TIS-responders was significantly higher in the
IVIG (37/47; 78.7%) than in the placebo group (21/48; 43.8%; P ¼ .0008). Least
square means for change from Baseline to Week 16 were -10.3 and -2.3 for IVIG
versus placebo in CDASI total activity score and -0.7 versus -0.1 for total damage.
Differences between arms were statistically significant for activity (-8.0: 95% CI
-11.5, -4.6; P \.0001) and damage (-0.6: 95% CI -1.1, -0.1; P ¼.0304). After switch to
IVIG, placebo patients attained similarly improved disease control at Week 40. This
is the first large international phase III randomized, placebo-controlled trial
demonstrating the efficacy of IVIG treatment to improve muscle as well as skin
symptoms in dermatomyositis patients.
Commercial Disclosure: The clinical trial was 100% sponsored by Octapharma.
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Efficacy of nemolizumab in atopic dermatitis: Rapid impact on
EASI and SCORAD components
Jean-David Bouaziz, MD, PhD, Department of Dermatology, Paris VII
Sorbonne Paris Cite University Assistance Publique e H^
opitaux de
Paris, Paris, France; Andreas Pinter, MD, Department of Dermatology,
Venereology, and Allergology, University Hospital Frankfurt am Main, Frankfurt
am Main, Germany; Afsaneh Alavi, MD, Department of Medicine, Division of
Dermatology, University of Toronto, Toronto, Ontario, Canada
Background: Nemolizumab is an interleukin 31 receptor inhibitor in phase 3 for
atopic dermatitis (AD). Common AD scores SCORing Atopic Dermatitis (SCORAD)
and Eczema Area and Severity Index (EASI) help delineate action of nemolizumab.
Methods: Post-hoc analysis of phase 2b data comparing nemolizumab 30 mg (SC
q4wk after a 60 mg loading dose, n ¼ 50) vs placebo (n ¼ 44) both plus steroids in
patients with baseline EASI score $16. Analysis of SCORAD and EASI components,
including SCORAD itch and sleep VAS scores.
Results: Demographics were similar between groups, including baseline
SCORAD/EASI overall and component scores. Moderate disease in ;60% of
subjects, severe in ;40%. By week 16, LSMean decrease in total SCORAD score
was 57.1% nemolizumab vs 28.2% placebo (P \.001), with separation apparent at
week 1 (-26.7% vs -13.3% placebo, P \ .001). Week 16 SCORAD ratings of
mild/absent for nemolizumab vs placebo were: dryness 55.3% vs 38.7%; papulation
80.8% vs 50.0%; erythema 68.0% vs 42.1%; excoriation 95.7% vs 56.8%; lichenification 63.9% vs 52.3%; and oozing 97.9% vs 84.6%. Separation on SCORAD VAS
was also seen by week 1 (P \.001 for all timepoints). At week 16, overall EASI score
decreased 68.6% vs 42.6% placebo; mean decreased erythema 64.1% vs 36/4%;
decreased excoriation 84.6% vs 26.3%; decreased papulation 68.6% vs 37.5%; and
decreased lichenification 60.2% vs 43.7%. Nemolizumab was safe with nasopharyngitis and respiratory infection most commonly seen.
Conclusion: Improvement of the clinical signs of AD as indicated by SCORAD
components were apparent at week 1 and increased through week 16.
Commercial Disclosure: Study sponsored by Galderma
Development, LLC.
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Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by anatomic region: Pooled analysis from two randomized
phase 3 studies
Eric L. Simpson, MD, MCR, Oregon Health & Science University,
Portland, OR; Robert Bissonnette, MD, FRCPC, Innovaderm Research, Montreal,
QC, Canada; Linda F. Stein Gold, MD, Henry Ford Health System, Detroit, MI
Atopic dermatitis (AD) is a highly pruritic inflammatory skin disease. Two phase 3
studies (TRuE-AD1/TRuE-AD2) enrolled patients aged $12 years with AD for $2
years, an Investigator’s Global Assessment (IGA) score of 2/3, and 3%e20% affected
body surface area. Patients (total N ¼ 1249; median age, 32 years) were randomized
(2:2:1) to twice-daily 0.75% ruxolitinib (Janus kinase [JAK] 1/JAK2 inhibitor) cream,
1.5% ruxolitinib cream, or vehicle cream for 8 weeks of double-blind treatment, and
thereafter continued in a long-term, 44-week period of the studies. In this pooled
analysis, mean percentage change from baseline in Eczema Area and Severity Index
(EASI) anatomic region subscores is reported up to Week 8 (n ¼ 1208). For the head
and neck region, patients applying 0.75%/1.5% ruxolitinib cream (vs vehicle)
achieved mean improvements of 59.3%/55.8% (vs 13.4%), 70.4%/71.3% (vs 22.4%),
and 70.0%/78.7% (vs 45.0%) at Weeks 2, 4, and 8, respectively (all P\.0001). Results
were similar for the upper limbs region (48.5%/54.7% [vs 13.3%], 66.6%/70.3% [vs
25.0%], and 73.5%/74.9% [vs 35.1%] all P \.0001). For the trunk region, patients
achieved mean improvements of 49.8%/60.0% (vs 12.1%), 67.3%/73.8% (vs 15.0%),
and 72.7%/81.0% (vs 15.6%) at Weeks 2, 4, and 8, respectively (all P\.0001). Similar
results were observed for the lower limbs region (46.0%/48.2% [vs 16.3%],
65.9%/66.2% [vs 13.9%], and 76.3%/74.9% [vs 39.8%]; all P \.0001). Ruxolitinib
cream was well tolerated, with an adverse event profile similar to vehicle. In
summary, ruxolitinib cream demonstrated significant improvements vs vehicle in
patients with AD across anatomic regions as early as Week 2.
Commercial Disclosure: This study was funded by Incyte Corporation
(Wilmington, DE).
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